VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 62,700 shares, an increase of 22.2% from the May 31st total of 51,300 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 92,100 shares, the short-interest ratio is currently 0.7 days.

Hedge Funds Weigh In On VYNE Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of VYNE Therapeutics in the first quarter worth approximately $50,000. Parkman Healthcare Partners LLC purchased a new stake in VYNE Therapeutics in the fourth quarter worth approximately $1,623,000. Finally, Eventide Asset Management LLC bought a new stake in VYNE Therapeutics in the 4th quarter worth approximately $3,249,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Stock Down 2.5 %

Shares of VYNE opened at $1.92 on Tuesday. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $6.79. The company has a market capitalization of $27.90 million, a P/E ratio of -0.35 and a beta of 1.33. The firm has a 50 day moving average of $2.42 and a 200 day moving average of $2.35.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. VYNE Therapeutics had a negative return on equity of 56.75% and a negative net margin of 6,874.47%. On average, sell-side analysts expect that VYNE Therapeutics will post -0.77 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a research report on Friday, June 14th.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.